Did you know this version of Internet Explorer is out of date?

To get the latest experience from our website, please upgrade your browser.

Have a drug or medical device concern?



Sort By
Drugwatch.com Author

Staff WriterStaff Writer

sorting white and blue Pradaxa pills

Pradaxa Back Under Review by the FDA

FDA officials will again review Pradaxa, one of the best-selling blood thinners on the market that is also linked to accidental, uncontrollable bleeding. The review by the U.S. Food and Drug...

FDA stamp of approval

FDA Approves Farxiga to Treat Type 2 Diabetes

This article was updated to include U.S. Food & Drug Administration warnings for ketoacidosis and kidney injury. The U.S. Food and Drug Administration in early January approved a...

Johnson & Johnson logo

Johnson & Johnson Shifting from Devices to Drugs in 2014

Drugmaker Johnson & Johnson is shifting its focus from medical devices and diagnostic equipment to pharmaceuticals, a strategy that will give Merck and Pfizer a good amount of competition this year. Although...

X-ray of skeleton running with knee pain

Active Lifestyles Increase Knee Replacement Surgeries in Younger Adults

The number of total knee replacement surgeries doubled in the U.S during the last decade, a recent study shows. A 2013 report published in the Journal of Bone and Joint Surgery showed that more...

Takeda headquarters in Japan

Takeda Scraps Development of Experimental Type 2 Diabetes Drug

Japanese pharmaceutical company Takeda is dropping plans to develop diabetes drug fasiglifam (TAK-875) because clinical trials showed participants developed dangerous side effects, including possible...

Cymbalta pill

Eli Lilly Faces Financial Hurdles over Loss of Cymbalta Patent

Eli Lilly is banking that new drugs will counter the massive drop in profits from losing exclusivity of its top-selling antidepressant Cymbalta. ...

Free Case Review